Audit: QRS - Magnesium Lactate for Health & Longevity
Audit conducted on 23/08/2026 08:27 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Protocol values, contraindications, interactions, benefit/risk items, monitoring targets and cadence all trace to ER Therapeutic Protocol, Key Interactions & Contraindications, Expected Benefits, Potential Risks & Side Effects and Monitoring Protocol & Defining Success. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | No empty-state or hedged ER passage is carried into the QRS in altered form; time_2_sub reproduces the ER’s “reached significance only in people treated for high blood pressure or already low in magnesium”. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | The ER’s “Absolute contraindication to unreported use” for neuromuscular blocking agents is kept in the Contraindications gate, not demoted to Key Interactions. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | No content from ER Benefit-Modifying Factors or Risk-Modifying Factors appears in the gates; gate content comes solely from Key Interactions & Contraindications. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, citations, author names, NCT identifiers or brand names (Mag-Tab SR, MLD10) appear anywhere in the QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind in the QRS body. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Matches the ER’s measured, delivery-vehicle framing throughout. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Quantified thresholds and ranges with plain-language explanation; the asymmetry (“gains concentrate where measured magnesium is genuinely low”) is presented as actionable rather than discouraging. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Uses impersonal constructions (“Documented deficiency is treated at the higher end”, “Split dosing preferred”). |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperatives directed at a reader; gates are stated as conditions, not instructions. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No “recommend”, “advise”, or “should” constructions in the QRS voice. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns present. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Terms are spelled out in full (“Estimated glomerular filtration rate”, “Glycated hemoglobin”, “Red blood cell magnesium”) rather than abbreviated. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Gate and tier items are single clauses; no mechanistic rationale carried over. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed: no direct address anywhere in the sheet. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Monitoring card assumes red-cell magnesium and 24-hour urinary collection — tests a proactive optimiser would pursue. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Split dosing, 8–12 week repletion phase and non-standard-panel assays are presented without hedging on effort. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | No simplified “just take a tablet” framing; the sheet is built around measurement-gated use. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | At-a-glance states the split explicitly: gains concentrate in the measurably low; in the replete only the digestive burden remains. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “anti-aging” does not occur; the page title uses “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | “loose stools”, “bowel” and “diarrhea” are the ER’s own clinical register; no consumer-grade substitutes such as “pills” or “tummy trouble”. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed headings match the template byte-for-byte (lines 445, 491, 540, 571, 583, 604, 626, 630–632, 759). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 27 distinct template variable names are present, with marker_#_* expanded to 8 rows and qualitative_item_# to 6 items. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | <span website="evidence_review">, <span website="audit"> and <span website="full_review"> are unchanged; CSS, footer disclaimer and structural comments are identical to the template. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section that feeds the QRS is empty. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | action_1_label “Standard supplemental dose”, action_2_label “Single versus split dosing” and action_3_label “Repletion versus maintenance” reproduce the ER Therapeutic Protocol bold labels verbatim. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Monitoring marker names and qualitative items are taken verbatim from the ER Monitoring Protocol & Defining Success table and list; time-to-effect cell labels are drawn from the ER’s own terms in that bullet. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji present; the ER’s “⚠️ Conflicted” markers were correctly stripped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed to single-clause items with mechanisms and citations stripped; no section carries elaborated ER prose. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Comment opens at line 2, immediately after <!doctype html> on line 1. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- at line 3, closing --- at line 13, comment closed at line 14. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no metadata value is repeated in the header or body. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, and it contains a colon requiring it. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: magnesium_lactate_2026-0823-0256_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md badge version. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0823-0815. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the file on disk: magnesium_lactate_2026-0823-0256_Opus_QRS.html. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys; git_issue: 5384 and git_user: evipedia-4 are unquoted and trimmed. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Magnesium Lactate for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “Magnesium Lactate for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: “08/23/2026”, correct reformatting of 2026-0823-0815. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header contains only the title and the template subline; the ER’s “Also known as” line was not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Compresses the ER Conclusion opening (“delivery vehicle, not a substance with effects of its own”) and its who-benefits paragraph into a decision-oriented statement. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 59 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Delivery-vehicle framing and the dissolution/loose-stool trade-off from ER line 505; the “measured magnesium is genuinely low” and “excreted within hours / only the digestive burden remains” clauses from ER line 507. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; vocabulary is limited to “delivery vehicle”, “absorbed”, “bowel”, “loose stools”, “excreted”, “digestive burden”. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years, sample sizes or p-values. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numeric results of any kind. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All five items map to ER lines 335 and 347–350. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All four “Populations who should avoid Magnesium Lactate” bullets plus the neuromuscular-blocking-agent absolute contraindication are present — five of five. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Lines 574–578: five discrete <li> elements inside the span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Explanatory glosses were stripped (e.g., ER’s “(a serious delay in the heart’s electrical conduction)” and “in whom magnesium can worsen weakness”); no trailing dash clauses remain. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “below 30”, “Second- or third-degree”, “unless the product is confirmed to be the L-isomer” and the (rocuronium, vecuronium, succinylcholine) drug list are all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER names such populations and the section is correctly populated rather than empty. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All nine items map to ER lines 325–343. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Nine of the ER’s ten interaction bullets are present; the tenth (neuromuscular blocking agents) is correctly placed in the Contraindications gate instead. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Lines 586–594: nine discrete <li> elements inside the span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Caution/Monitor verdicts, mechanisms and separation windows from the ER bullets are all stripped; no trailing dash clauses remain. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Every ER drug list is retained (ciprofloxacin/levofloxacin/moxifloxacin; doxycycline/minocycline; alendronate/risedronate/zoledronate; omeprazole/esomeprazole/pantoprazole; furosemide/hydrochlorothiazide), as is the “above 142 mg daily” zinc threshold. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER names ten such interactions and the section is correctly populated. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells trace to ER Therapeutic Protocol lines 372, 376 and 386. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose, dosing schedule and repletion-versus-maintenance duration are the three load-bearing execution decisions in that section. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies more than three actionable aspects and all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine variables carry ER-derived content; no placeholders remain. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Magnesium status, blood pressure and sleep are exactly the three latencies given in ER line 431. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Magnesium status and blood pressure are the two ER High-tier benefits; sleep-onset latency is Medium and comes last. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies three distinct time-to-effect aspects and all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine variables carry ER-derived content: time_1_sub from the ER monitoring paragraph’s “roughly one red-cell turnover”, time_2_sub from ER line 163, time_3_sub from ER lines 431 and 448 (“the effect is largest in older adults”). |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information and the section is retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All fifteen items map to the ER’s fifteen benefit headings. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present at lines 542, 547, 554 and 562. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the ER heading reduced to a noun phrase; no magnitudes, confidence intervals or study details carried over. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content appears in any benefit item. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers carry items in the ER, so no span needed hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All five items map to the ER’s five risk headings. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present at lines 606, 609, 612 and 618. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Relative risks, event counts and mechanisms from the ER magnitude lines are all omitted. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content appears in any risk item; the ER’s “(dangerously high blood magnesium)” gloss was correctly dropped. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers carry items in the ER, so no span needed hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | All eight rows reproduce the ER Monitoring Protocol & Defining Success biomarker table (ER lines 463–472). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | Eight of eight: serum magnesium, red blood cell magnesium, eGFR, 24-hour urinary magnesium, serum potassium, serum calcium, glycated hemoglobin, office and home blood pressure — with targets matching the ER exactly. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 748–753 reproduce the ER’s 8–12 week recheck, 6–12 month steady-state interval, annual kidney function and conditional blood-pressure/HbA1c cadence. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All six items reproduce the ER’s “Qualitative markers worth tracking alongside the labs” list (ER lines 476–481). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | Six of six, verbatim: sleep onset and night-time awakenings, nocturnal cramps and eyelid twitching, stool consistency and frequency, daytime energy and exercise recovery, stress reactivity and irritability, headache or migraine frequency. |
Issues 23/08/2026 08:27
Pass rate 100.00%. No issues found.
Issues 23/08/2026 08:19
- 7.2 — At-a-glance exceeds word limit: The [at_a_glance] span (lines 433–439) contains 64 words against the 60-word maximum.
Fixes 23/08/2026 08:19
- 7.2 — At-a-glance trimmed to word limit: Condensed the [at_a_glance] span from 64 to 59 words by dropping “of the mineral” and tightening the two closing clauses (“Gains concentrate where measured magnesium is genuinely low. When it is already normal, …”), leaving every ER-supported fact intact.